Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Yahoo! Finance
– Additional Phase 2 studies ongoing: ALTO-101 in schizophrenia and ALTO-100 as an adjunctive treatment in bipolar depression – – Key learnings from ALTO-100 Phase 2b MDD trial including clinically meaningful effect observed in a pre-specified secondary analysis and evidence of stratification using the pre-specified enrichment biomarker in patients with confirmed drug compliance – – Strong cash position of approximately $182 million is expected to fund planned operations into 2027, and through at least four additional clinical study readouts – MOUNTAIN VIEW, Calif., November 12, 2024 BUSINESS WIRE )--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent corporate progress. "We have sharpened our clinical focus, which we expect will propel us forward to
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- The Schall Law Firm Wants Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Securities Fraud Accesswire
- Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Affected Investors Are Urged To Contact The Schall Law FirmAccesswire
- The Schall Law Firm Invites Stockholder Participation In An Inquiry Into Alto Neuroscience, Inc. For Securities FraudAccesswire
- Alto Neuroscience Inc Is Being Investigated For Violating Securities Laws And Investors With Losses Are Encouraged To Contact The Schall Law FirmAccesswire
- The Schall Law Firm Wants Shareholders To Join An Inquiry Into Alto Neuroscience, Inc. For Fraud Accesswire
ANRO
Earnings
- 11/12/24 - Beat
ANRO
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- ANRO's page on the SEC website